Viz.ai vs Tempus AI
A detailed comparison to help you choose between Viz.ai and Tempus AI.
🏆
Verdict: Tempus AI wins
Tempus AI scores 4.1/5, edging out Viz.ai at 4.0/5. Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access.
Viz.ai AI care coordination for time-sensitive conditions | Tempus AI AI for precision medicine and clinical genomics | |
|---|---|---|
| Rating | 4.0 (1 review) | 4.1 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $500/mo | From $1000/mo |
| Best For | Hospitals and health systems running stroke, PE or other time-sensitive pathways that want FDA-cleared detection wired directly into specialist mobilization — and can support a full IT integration. | Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | ssoteam features |
| Visit Viz.ai → | Visit Tempus AI → |
Viz.ai
Pros
- + More than 50 FDA-cleared algorithms — regulated device claims, not marketing benchmarks
- + The alert loop is engineered for the clock: in my demo session the mobile alert carried the CTA images with one-tap access, no PACS detour
- + Medicare NTAP of roughly $1,040 per qualifying Viz LVO use — a payer-level validation rare in clinical AI
- + Suite model (Neuro, Cardio, Vascular, Pulmonary, Trauma, Radiology) reuses one coordination layer, so adding a pathway is not buying a new product
- + Peer-reviewed outcomes evidence and ~1,700 hospital deployments (third-party reported) give procurement teams real reference sites
Cons
- - Zero price transparency: no pricing page, no self-serve, no trial — every deal is quoted per facility
- - Requires deep hospital IT integration (PACS, on-call routing), so time-to-value is measured in months
- - Detection coverage is a fixed list of time-sensitive conditions; no incidental-findings or general radiology workflow
- - Economic case leans on stroke-center volume; smaller hospitals may not recoup the subscription via NTAP
- - Third-party revenue trackers (~$40M in 2023) suggest the business is still scaling against stated ARR ambitions
Tempus AI
Pros
- + FY2025 revenue of $1.3B with 126% net revenue retention and >$1.1B remaining contract value — verifiable public-company financials, not marketing claims
- + Complete assay portfolio in one relationship: xT/xR comprehensive profiling, xF+ liquid biopsy, MRD monitoring, Ambry hereditary testing and OneOme pharmacogenomics (national launch July 2026)
- + Tempus One answered voice queries against the patient's own clinical and molecular profile in my testing, with report citations instead of generic text
- + Paige Predict extends the platform into digital pathology — 123 biomarkers predicted from standard H&E slides across 16 cancer types (vendor-published validation)
- + Trial matching is built into the report workflow, which is the practical bottleneck for oncology coordinators
Cons
- - No self-serve access, no trial, and no published pricing of any kind — the $1,000 entry figure floating around listings could not be verified
- - Oncology-first scope; primary care and non-oncology specialties have little reason to engage
- - Still net-loss-making (-$245.0M in 2025), and the portfolio is stitched from four recent acquisitions (Ambry, Paige, OneOme, Deep 6)
- - Model-performance and data-library claims are company-published; independent third-party validation is thinner than the press-release volume suggests
- - Enterprise sales motion means long procurement cycles for health systems
Frequently Asked Questions
Which is better, Viz.ai or Tempus AI?▼
Tempus AI scores higher at 4.1/5 vs 4.0/5 for Viz.ai, making it the better-rated option in our comparison.
What is the difference between Viz.ai and Tempus AI?▼
Viz.ai: Viz.ai is a care coordination platform that uses AI to detect time-sensitive conditions on medical imaging and alert the right specialist team. Tempus AI: Tempus AI runs clinical and genomic sequencing and builds the diagnostics and data products used in precision oncology and other specialties.
Is Viz.ai or Tempus AI more affordable?▼
Viz.ai starts at €500/mo, Tempus AI starts at €1000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.